20132018

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Federica Capozzi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.

Mesiano, G., Grignani, G., Fiorino, E., Leuci, V., Rotolo, R., D’Ambrosio, L., Salfi, C., Gammaitoni, L., Giraudo, L., Pisacane, A., Butera, S., Pignochino, Y., Basiricó, M., Capozzi, F., Sapino, A., Aglietta, M. & Sangiolo, D., Nov 2 2018, In : OncoImmunology. 7, 11, e1465161.

Research output: Contribution to journalArticle

  • PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

    Pignochino, Y., Capozzi, F., D'Ambrosio, L., Dell'Aglio, C., Basiricò, M., Canta, M., Lorenzato, A., Vignolo Lutati, F., Aliberti, S., Palesandro, E., Boccone, P., Galizia, D., Miano, S., Chiabotto, G., Napione, L., Gammaitoni, L., Sangiolo, D., Benassi, M. S., Pasini, B., Chiorino, G. & 2 others, Aglietta, M. & Grignani, G., Apr 28 2017, In : Molecular Cancer. 16, 1, 86.

    Research output: Contribution to journalArticle

  • PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.

    Pignochino, Y., Capozzi, F., D'Ambrosio, L., Dell'Aglio, C., Basiricò, M., Canta, M., Lorenzato, A., Vignolo-Lutati, F., Aliberti, S., Palesandro, E., Boccone, P., Galizia, D., Miano, S., Chiabotto, G., Napione, L., Gammaitoni, L., Sangiolo, D., Benassi, M. S., Pasini, B., Chiorino, G. & 2 others, Aglietta, M. & Grignani, G., Apr 28 2017, In : Molecular Cancer. 16, 1, p. 1-15 15 p.

    Research output: Contribution to journalArticle

  • Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: A non-randomised phase 2 clinical trial

    Grignani, G., Palmerini, E., Ferraresi, V., D'Ambrosio, L., Bertulli, R., Asaftei, S. D., Tamburini, A., Pignochino, Y., Sangiolo, D., Marchesi, E., Capozzi, F., Biagini, R., Gambarotti, M., Fagioli, F., Casali, P. G., Picci, P., Ferrari, S. & Aglietta, M., 2015, In : The Lancet Oncology. 16, 1, p. 98-107 10 p.

    Research output: Contribution to journalArticle

  • The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma

    Pignochino, Y., Dell'Aglio, C., Inghilleri, S., Zorzetto, M., Basiricò, M., Capozzi, F., Canta, M., Piloni, D., Cemmi, F., Sangiolo, D., Gammaitoni, L., Soster, M., Marchiò, S., Pozzi, E., Morbini, P., Luisetti, M., Aglietta, M., Grignani, G. & Stella, G. M., May 8 2015, In : BMC Cancer. 15, 1, 374.

    Research output: Contribution to journalArticle